Related Experiment Videos
Angiogenesis in rheumatoid arthritis.
N Maruotti1, F P Cantatore, E Crivellato
1University of Foggia Medical School, Foggia, Italy.
Histology and Histopathology
|February 24, 2006
Summary
Rheumatoid arthritis involves angiogenesis, with imbalances in blood vessel growth factors and inhibitors contributing to persistent joint inflammation. Understanding these angiogenic mediators is key to managing rheumatoid arthritis progression.
Area of Science:
- Rheumatology
- Molecular Biology
- Immunology
Background:
- Rheumatoid arthritis (RA) pathogenesis is closely linked to angiogenesis.
- Key angiogenic mediators are present in the synovium and tenosynovium of rheumatoid joints.
Purpose of the Study:
- To review the role of angiogenic mediators in rheumatoid arthritis.
- To highlight the imbalance between inducers and inhibitors of angiogenesis in RA joints.
Main Methods:
- Review of scientific literature on angiogenesis in rheumatoid arthritis.
- Identification and categorization of angiogenic factors and inhibitors involved in RA.
Main Results:
- Vascular Endothelial Growth Factor (VEGF) and its receptors are central to angiogenesis regulation in RA.
- Numerous other mediators, including PDGF, FGF-2, EGF, IGF, HGF, TGF-beta, TNF-alpha, interleukins (IL-1, IL-6, IL-8, IL-13, IL-15, IL-18), angiogenin, PAF, angiopoietin, and endoglin, promote angiogenesis in RA.
- Angiogenic inhibitors such as endostatin and thrombospondins (TSP-1, TSP-2) are also present.
Conclusions:
- The persistence of inflammation in rheumatoid joints results from an imbalance between pro-angiogenic and anti-angiogenic factors.
- Targeting these angiogenic pathways may offer therapeutic strategies for rheumatoid arthritis.